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Summary 06-alkylguanine-DNA-alkyltransferase (ATase) activity was measured in extracts of peripheral
blood mononuclear cells (PMCs) taken from eight patients at various times during 5 days of oral treatment
with temozolomide (150 mgm-2 days 1-5). Pretreatment ATase levels ranged from approximately 70 to
600 fmol per mg of protein. Depletion of PMC ATase was seen within 4 h of the first dose of temozolomide
and had a median nadir of 52.9% and values ranging from 44.4% to 71.0% of pretreatment levels. There was
a correlation between the extent of ATase depletion (pretreatment minus nadir level) and the pretreatment
ATase level (r = 0.97). A progressive depletion of ATase was observed during the 5 days of continuous
temozolomide therapy with median ATase activities of 66.3%, 52.5%, 39.5%, 30.5% and 28.9% of the
pretreatment values at days 2, 3, 4, 5 and 6 respectively. This suggests that the schedule-dependent anti-
tumour activity of temozolomide seen in experimental models and clinics may be related to a cumulative
depletion of ATase.
Temozolomide (CCRG 81045; M&B 39831; NSC 362856)
was recently selected for clinical trials and has shown promis-
ing anti-tumour activity against high-grade gliomas,
melanoma and mycosis fungoides (Newlands et al., 1992;
O'Reilly et al., 1993). In contrast to dacarbazine (DTIC) or
CB1O-277, which require metabolic activation, temozolomide
undergoes spontaneous chemical degradation to generate the
cytotoxic monomethyl triazene, 5-(3-methyl-1-triazeno)
imidazole-4-carboxamide (MTIC) (Figure 1) (Stevens et al.,
1987; Tsang et al., 1991), which methylates DNA, generating
among 12 other DNA lesions 06-methylguanine (06-MeG).
There is increasing experimental evidence to suggest that the
anti-tumour activity of this class of drugs is linked to the
alkylation of the 06 position of guanine in DNA and that
endogenous expression of 06-alkylguanine-DNA alkyltrans-
ferase (ATase) may be a major factor in resistance to such
agents (D'Incalci et al., 1988; Margison & Connor, 1990;
Pegg & Byers, 1992); ATase transfers the methyl group from
06-MeG to an internal cysteine residue in an autoinactiv-
ating, stoichiometric reaction. A similar mode of drug resist-
ance applies to the chloroethylating nitrosoureas; ATase pre-
vents the formation of the cytotoxic interstrand cross-links
which are produced in a two-step reaction from the monoad-
duct 06-chloroethylguanine, which has itself been shown to
be a substrate for ATase (Tong et al., 1982; Gonzaga et al.,
1992; Baer et al., 1993). The strongest evidence for the
cytotoxic effects of 06-alkylguanine in DNA comes from
experiments which show that the expression of a transfected
prokaryotic or eukaryotic ATase cDNA in mammalian cells
protects them against the toxic effects of these agents (Bren-
nand & Margison, 1986; Kataoka et al., 1986; Samson et al.,
1986; Jelinek et al., 1988; Kaina et al., 1991).
While the majority of human tumours examined so far
express ATase activity (D'Incalci et al., 1988), it is possible to
sensitise resistant tumour cells in culture or xenografts by
pretreatment with methylating agents (Zlotogorski & Erick-
son, 1983, 1984; Gibson et al., 1986) or the modified base
06-benzylguanine (Dolan et al., 1991), which renders them
sensitive to the cytotoxic effects of subsequent treatment with
methylating or chloroethylating agents. Two- to 12-fold in-
creases in sensitivity to these agents have been observed with
tumour cell lines which have high levels of AT4se: these
include colon (Karran & Williams, 1985; Baer et al., 1993),
melanoma (Dempke et al., 1987), glioma (Aida et al., 1987;
Baer et al., 1993), breast (Baer et al., 1993) and leukaemic
cell lines (Gerson et al., 1988).
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The kinetics of the inactivation of ATase during the repair
of 06-MeG and the subsequent resynthesis of ATase are
parameters which may predict an individual patient response
to treatment. We have previously found a depletion ofATase
in peripheral blood mononuclear cells (PMCs) of patients
receiving a single intravenous bolus of dacarbazine or 24 h
continuous infusion of CB10-277 (Lee et al., 1991, 1992,
1993a). ATase depletion was also seen in the tumour biopsies
of patients receiving the latter treatment schedule (Lee et al.,
1992). Furthermore, using DTIC, very large inter-patient
variations in the extents and rates of ATase depletion were
observed (Lee et al., 1991, 1993a). In the present study we
therefore examined the kinetics of ATase depletion in PMCs
of eight patients with metastatic melanoma treated with the
direct-acting agent temozolomide on five consecutive days. In
five patients, changes in PMC ATase levels were also
measured at various times during the 24 h after the first dose
of temozolomide. In contrast to daily temozolomide adminis-
tration, a single intravenous bolus of this drug was not
associated with any tumour xenograft response in rodent
models (Stevens et al., 1987) or in clinics (Newland et al.,
1993) and we have therefore also compared ATase levels
during 24 h of a single dose of temozolomide with those after
1-5 days of treatment.
Materials and methods
Chemicals
Temozolomide was supplied by the Department of Phar-
maceutical Sciences, Aston University, Birmingham, UK.
Dacarbazine was obtained from Bayer UK (Newbury, UK)
and CBI0-277 from the National Cancer Institute (Bethesda,
MD, USA).
Treatment ofpatients
For this clinical study, temozolomide was formulated at
Strathclyde University.in hard gelatin capsules containing 20,
50 or 100 mg. All patients had metastatic melanoma and the
clinical characteristics are shown in Table I. For the first
treatment cycle, temozolomide was administered orally at
150 mg m-2 daily for five consecutive days. For subsequent
treatment, patients received oral temozolomide (200 mg m-2)
daily on 5 consecutive days and this was repeated every 28
days. Serial blood samples were collected at 0 h, 1 h, 2 h, 3 h,
4 h, 6 h and 24 h in five patients and at 48 h, 72 h, 96 h,
120 h in three of these and an additional five patients receiv-
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Figure 1 Metabolism of DTIC and decomposition pathway of
temozolomide. Abbreviations used: AIC, 5-aminoimidazole-4-
carboxamide; HMTIC, 5-(3-hydroxymethyl-3-methyl-1-triazenyl)
imidazole-4-carboxamide; MTIC, 5-(3-methyl-I-triazeno)imi-
dazole-4-carboxamide.
ing daily temozolomide (150 mg m2 daily from days 1 to 5).
Blood was dispensed into 20 ml universal containers contain-
ing 0.5 ml of0.5% EDTA and kept at 4°C before isolation of
PMCs. Signed informed consent was obtained following the
guidelines of the local health authority ethical committee.
The phase II trial of temozolomide was carried out under the
auspices of the Cancer Research Campaign (UK) Clinical
Trials Committee.
Isolation ofPMC, ATase extraction and assay
This was carried out as described previously (Lee et al.,
1991). Briefly, the PMCs were isolated by centrifugation on
Ficoll (Pharmacia, Uppsala, Sweden) (Boyum, 1968),
Results
Effect oftemozolomide on PMC ATase levels
In this series of patients, there was a wide range of pretreat-
ment PMC ATase levels ranging from 69 to 593 fmolmg-'
protein (mean 275 ± 182 fmolmg-' protein) (Table I). Deple-
tion of PMC ATase was seen within 4 h of the first oral dose
of temozolomide and the median nadir was 52.9% with
values ranging from 44.4% to 71.0% of pretreatment levels
in the five patients studied (Figure 2). Using repeated
measurement analysis and Duncan's multiple range test,
nadir ATase appears to occur between 2 and 6 h after
chemotherapy, Taking each individual as their own control,
recovery of PMC ATase activity greater than 20% was seen
by 24 h in three of the five patients (see Figure 2).
Following 5 days' oral administration, a cumulative and
progressive depletion ofATase was observed in eight patients
(see Figure 3) with median ATase levels of 66.3%, 52.5%,
39.5%, 30.5% and 28.9% of pretreatment values at days 2, 3,
4, 5 and 6 respectively. In two patients on day 7, 48 h after
the last temozolomide dose, ATase levels had recovered to
42.7% and 48.3% of the pretreatment levels, the nadirs in
these patients being 25.6% and 35.0% of the pretreatment
levels respectively. Using repeated measurement analysis and
Duncan's range test, the nadir ATase activity appears to
occur between days 4 and 6. There was a linear relationship
between the pretreatment ATase level and the extent of
ATase depletion (pretreatment minus nadir ATase level) with
a correlation coefficient of0.97 (Figure 4). The corresponding
data from Lee et al. (1991, 1992) are also presented in Figure
4 and correlation coefficients of 0.88 and 0.96 were calculated
for DTIC and CB10-277 respectively.
Discussion
In the present study, we clearly demonstrate that temo-
zolomide is effective in depleting ATase activity in PMCs and
that the nadir of activity following a single dose is around
2-6h after treatment (Figure 2). If the ATase depeletion
(pretreatment minus nadir levels) seen had been a conse-
quence of temozolomide-mediated methylation of DNA in
PMCs and the subsequent autoinactivation of ATase by the
repair of 06-MeG thus generated, it would have been pre-
dicted that, particularly with an agent not requiring
metabolic activation, the actual amount of ATase inactivated
in this way would be relatively constant, assuming that drug
uptake and ATase resynthesis rates were consistent. How-
ever, we found that the extent of ATase inactivation varied
Table I Patient characteristics
Age (years)! ATase (fmolmg' ± s.d.)
Name sex (M/F) Metastatic sites Initial Nadir"
JP 40/F Nodes, liver, lung 140 ± 6.9 NM
MS 45/M Liver, lung 434 ± 5.7 NM
YA 26/F Nodes, soft tissues 286 ± 6.5 123 ± 4.4
MC 39/F Lung, liver, bone 459 ± 1.8 107 ± 7.2
MF 68/F Skin, nodes 197 ± 12.8 54± 1.3
IC 58/F Lung, liver, nodes 300 ± 4.8 105 ± 1.0
AW 75/M Lung, nodes, liver 593 ± 17.3 152 ± 2.0
KH 54/M Lung, nodes, liver 243 ± 16.6 35 ± 2.3
GA 66/M Skin 69 ± 4.9 14 ± 0.6
MA 59/M Skin, nodes 257 ± 13.5 135 ± 2.2
'ATase nadir during daily temozolomide administration (see Figure 3). NM, not
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Figure 2 ATase activity (fmol mg-' protein) in PMCs of five
patients up to 24 h after the first temozolomide dose
(150 mg m-2).
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considerably from patient to patient, but that there was a
strong correlation between the extent of ATase depletion and
the pretreatment ATase level.
Although ATase depeletion would be expected to occur via
methylation of DNA in PMCs by temozolomide, the possi-
bility that this non-stoichiometric depletion of ATase was
due to a direct effect of temozolomide on the ATase itself
cannot be dismissed. Previous studies have shown that inac-
tivation of partially purified human ATase from CEM cells
can occur in vitro following incubation with a variety of
alkylating agents, including MNU, streptozotocin, BCNU,
chlorozotocin, CCNU and MeCCNU, and, of the agents
tested, methylmethanesulphonate was the most effective, pro-
ducing 50% inactivation at 70 JM (Brent, 1986).
Reanalysis of earlier results using DTIC and CB10-277
(Lee et al., 1991, 1992) also shows a correlation between
pretreatment ATase levels and the amounts of ATase inac-
tivated (Figure 4). Here too, the depletion may therefore be a
consequence of the direct reaction of the corresponding
metabolites with PMC ATase. That the kinetics of ATase
depletion with temozolomide were very similar to that
observed with DTIC (Lee et al., 1991) and CB1O-277 (Lee et
al., 1992), both of which require metabolic activation in
order to produce a methylating species (Figure 1), suggests
that the process of metabolic activation of the latter agents
occurs very rapidly and might not be the rate-limiting step in
ATase depletion.
Figure 4 Relationship between the extent of ATase depletion (A
ATase = pretreatment minus nadir ATase levels) and pretreat-
ment ATase level in patients receiving temozolomide, DTIC or
CB10-277. r = correlation coefficient.
If ATase depletion by alkylating agents in vivo is
predominantly a direct effect and not unique to PMC, one
possible consequence might be that the extent of ATase
inactivation would be greatest in those cells and tissues exp-
ressing the highest levels of enzyme. Thus, in tumour cells
which can express high ATase levels (Dolan et al., 1991),
sensitisation to killing by alkylating agents might be more
extensive than in bone marrow, which generally expresses
low levels of ATase (Gerson et al., 1985). Indeed, extrapola-
tion of the data in Figure 4 suggests that a threshold ATase
level exists below which no ATase depletion occurs. For
temozolomide and DTIC this value is 40-45 fmol mg-' pro-
tein; for CBI0-277, the value was about 10 fmol mg-',
although there were fewer patients in this study.
The post-nadir recovery of PMC ATase activity was
variable, but in none of the five patients studied was a return
to pretreatment levels observed. This residual deficit in ATase
was generally increased during the repeat daily administra-
tion of temozolomide such that, 24 h after the final dose,
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ATase levels were between 14.4% and 52.5% of the pretreat-
ment values (Figure 3). There was little inter-patient varia-
tion in the percentage decrease in ATase activity during the
schedule, despite wide variations in pretreatment ATase
levels, suggesting that depletion was possibly a direct effect
on ATase.
It has been shown that the anti-tumour activity of
temozolomide in tumour-bearing mice is schedule dependent
(Stevens et al., 1987), and a similar finding was reported with
51 patients treated with temozolomide (Newlands et al.,
1992). Thus, improved therapeutic effectiveness was noted
when temozolomide was given daily for 5 days compared
with single-dose administration. It does not seem
unreasonable to suggest that the greater effectiveness of the
daily treatment is related to the more extensive depletion of
ATase, assuming that a similar effect occurs in the tumour
cells. While tumour tissue has not been assessed in the pres-
ent study, we have previously shown that CB1O-277 is able to
deplete ATase levels in both PMCs and melanoma (Lee et
al., 1992).
If tumour sensitisation is a consequence of ATase deple-
tion, then it might be speculated from the present results that
response to treatment would be more extensive if the
temozolomide was given every 2-6 h, corresponding to the
ATase nadir found here after a single dose, rather than every
24 h, when recovery of ATase activity can occur. Indeed, in
the treatment of melanoma with DTIC/fotemustine combina-
tions, the schedule of fotemustine 4 h after DTIC was
designed to exploit the anticipated nadir of ATase activity
produced by DTIC (Lee et al., 1991) and produces better
response rates than the individual agents given alone (Lee et
al., 1993b). The possibility therefore of giving a
chloroethylating agent 2-6 h after the last of five doses of
temozolomide given every 2-6 h also seems worthy of con-
sideration.
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Abbreviations: ATase, 06-alkylguanine-DNA alkyltransferase; MNU,
N-methyl-N-nitrosourea; BCNU, 1,3-bis-(2-chloroethyl)-1-nitrosourea;
CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea; MeCCNU, 1-
trans-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea.
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